(PDF) P071 Variants Distribution and Heterogeneity of

P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.084

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

The Activity, Safety, and Evolving Role of Brigatinib in Patients With ALK-rearranged Non-Small Cell Lung Cancers

OncoTargets and Therapy

English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Multidisciplinary

English

P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

A Case of ALK- Rearranged Adenocarcinoma With Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

Journal of Thoracic Oncology

Respiratory Medicine

English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer

Cancer Research

Respiratory Medicine

English